Open AccessComparison of the effects of three kinds of IgYs, (normal, nanoliposomal and nanoparticle conjugated), which are produced against the small domains of DR5 protein on cancer cells
Author(s) -
Amirijavid Shaghaegh,
Entezari Maliheh
Publication year - 2018
Publication title -
iet nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.366
H-Index - 38
eISSN - 1751-875X
pISSN - 1751-8741
DOI - 10.1049/iet-nbt.2017.0123
Subject(s) - apoptosis , cancer cell , conjugated system , receptor , programmed cell death , cancer , drug delivery , extracellular , antibody , drug carrier , chemistry , liposome , microbiology and biotechnology , cancer research , biology , biochemistry , immunology , organic chemistry , genetics , polymer
Cancer treatment with several kinds of drugs, especially targets the apoptotic pathways nowadays. TNF‐related apoptosis‐inducing ligand (TRAIL) as one of the important members of death receptors, significantly trigger induction of apoptosis in cancer cells. Three conserved domains of Death receptor (DR5) protein extracellular domain, which are fortified cysteine, were chosen and chemically synthesised. Hens were immunised with nano‐liposomal peptides, and as a result the purified Immunoglobulin (IgYs) remarkably killed the cancerous MCF7 cells. The flow cytometric assay, confirmed the apoptotic death. Among several kinds of carriers that were used in this research, the nano‐liposomal and nanoparticle conjugated, both were acceptable choices for drug delivery. Furthermore, the IgY against DR5's small peptides with such carriers successfully reached the target and significantly killed the cancer cells via apoptosis.